EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP

Jens Tidemandsen iD, Vibeke Backer, Anne Sophie Homøe iD, Thomas H L Jensen, Kasper Aanæs, Howraman Meteran, Morten Hostrup, Lukas Moesgaard iD, Christiane Haase, Peter G Gibson

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.70073 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Jens Tidemandsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, , Denmark. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps, Rhinitis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies.

Objective

To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma.

Methods

In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup.

Results

Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient‐reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups.

Conclusions

Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSinusitisNasal PolypsRhinitisEndoscopyAsthmaHumansMaleFemaleMiddle AgedAdultChronic DiseaseInflammationAgedTreatment OutcomeParanasal SinusesInterleukin-5

Stichwörter der Autor:innen

biologics treatmentchronic rhinosinusitis with nasal polypsfunctional endoscopic sinus surgeryglobal airway hypothesistype 2 inflammation

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, , Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Respiratory Medicine, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.
  • Clinical and Experimental Physiology Group, The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
  • School of Medicine and Public Health, The University of Newcastle, New Lambton, New South Wales, Australia.

ORCID-Profile: Jens Tidemandsen, Anne Sophie Homøe, Lukas Moesgaard

Förderung

  • GlaxoSmithKline

Zitieren

APA

Tidemandsen, J., Backer, V., Homøe, A. S., Jensen, T. H. L., Aanæs, K., Meteran, H., Hostrup, M., Moesgaard, L., Haase, C., & Gibson, P. G. (2025). The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70073

Vancouver

Tidemandsen J, Backer V, Homøe AS, Jensen THL, Aanæs K, Meteran H, et al. The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.70073

BibTeX
@article{Tidemandsen2025,
  author = {Tidemandsen, Jens and Backer, Vibeke and Homøe, Anne Sophie and Jensen, Thomas H L and Aanæs, Kasper and Meteran, Howraman and Hostrup, Morten and Moesgaard, Lukas and Haase, Christiane and Gibson, Peter G},
  title = {The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.70073}
}
Kostenlos starten →